Citations 12
Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors
Matsui, Jennifer K. , Perlow, Haley K. , Raj, Rohit K., Nalin, Ansel P. , Lehrer, Eric J. , Kotecha, Rupesh , McClelland, Shearwood , Kendra, Kari , Williams, Nicole , Thomas, Evan , Beyer, Sasha , Blakaj, Dukagjin , Ahluwalia, Manmeet S. , Raval, Raju R. , Palmer, Joshua D. , Kendra, Kari , Palmer, Joshua D , Ahluwalia, Manmeet S , Perlow, Haley K , Trifiletti, Daniel M. , Owen, Dwight H , Presley, Carolyn J.
Biomedicines | September 7, 2022 | Volume: 10 | Issue: 9 | Pages: 2211
Brain metastases are a devastating sequela of common primary cancers (e.g., lung, breast, and skin) and have limited effective therapeutic options. Previously, systemic chemotherapy failed to demonstrate significant benefit in patients with brain metastases, but in recent decades, targeted therapies and more recently immune checkpoint inhibitors (ICIs) have yielded promising results in preclinical and clinical studies. Furthermore, there is significant interest in harnessing the immunomodulatory effects of radiotherapy (RT) to synergize with ICIs. Herein, we discuss studies evaluating the impact of RT dose and fractionation on the immune response, early studies supporting the synergistic interaction between RT and ICIs, and ongoing clinical trials assessing the benefit of combination therapy in patients with brain metastases.
Acute kidney injury in patients treated with immune checkpoint inhibitors
Short, Samuel , Sise, Meghan E. , Prosek, Jason, Madhavan, Sethu M. , Soler, María José , Ostermann, Marlies , Abudayyeh, Ala , Anand, Shuchi , Motwani, Shveta S. , Murakami, Naoka , Wanchoo, Rimda, Ortiz-Melo, David I. , Rashidi, Arash , Aggarwal, Vikram , Malik, Abhinav , Loew, Sebastian, Carlos, Christopher A., Chang, Wei‐Ting , Beckerman, Pazit , Mithani, Zain, Renaghan, Amanda DeMauro , Seigneux, Sophie de , Campedel, Luca , Shin, Daniel Sanghoon , Rangarajan, Sunil , Deshpande, Priya , Coppock, Gaia, Eijgelsheim, Mark, Lee, Meghan , Husain, Marium , García-Carro, Clara , Bermejo, Sheila , Lumlertgul, Nuttha , Seylanova, Nina , Flanders, Lucy , Isik, Busra , Mamlouk, Omar , García, Pablo , Kaghazchi, Aydin , Khanin, Yuriy, Kansal, Sheru, Wauters, Els , Chandra, Sunandana , Hsu, Raymond K. , Tio, Maria Clarissa , Mothi, Suraj Sarvode, Singh, Harkarandeep , Reynolds, Kerry L. , Cortazar, Frank B. , Leaf, David E. , Salem, Joe‐Elie , Gupta, Shruti , Kitchlu, Abhijat , Lee, Meghan D , Mamlouk, Omar , Lin, Jamie S , Leaf, David E , Murakami, Naoka , Soler, Maria Jose , Salem, Joe-Elie , Hsu, Raymond K , Ostermann, Marlies , Koessler, Thibaud , Gupta, Shruti , Herrmann, Sandra M. , Glezerman, Ilya G , Sprangers, Ben , Malik, A Bilal, Shah, Chintan V , Kitchlu, Abhijat , Seethapathy, Harish Shanthanu , Strohbehn, Ian A. , Owen, Dwight H , Schmidt-Ott, Kai Martin , Schrag, Deborah , Jhaveri, Kenar D.
Journal for ImmunoTherapy of Cancer | October 10, 2021 | Volume: 9 | Issue: 10 | Pages: e003467
Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. Methods We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI. Results ICPi-AKI occurred at a median of 16 weeks (IQR 8–32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3–10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI. Conclusions Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.